News for Healthier Living

Moffitt Study Shows Promise for New Treatment in Patients With Leptomeningeal Disease

Researchers at Moffitt Cancer Center have reported encouraging results from a phase 1B clinical trial showing that the immunotherapy drug avelumab, when combined with whole brain radiotherapy, may provide a safe and effective treatment option for patients with leptomeningeal disease, one of the most aggressive and difficult-to-treat complications of advanced cancer. The findings were published in Neuro-Oncology.

September 30, 2025


October 13 2025

October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025

October 5 2025

October 4 2025

October 3 2025

October 2 2025

October 1 2025

September 30 2025

September 29 2025